Latest Videos
In the current environment of precision treatments for cancer, what kind of genetic alterations can be categorized as actionable? For example, if the mutation is linked to an approved therapy in the solid tumor under study or another solid ...
Does FoundationOne’s comprehensive NGS have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically validated ...
How is genomic profiling helpful in identifying actionable molecular targets?
Successful targeted cancer therapies include trastuzumab for HER2-amplified breast cancer, imatinib in Philadelphia chromosome–positive CML, erlotinib in EGFR-mutated non-small cell lung cancer and vemurafenib in BRAF-mutant melanoma. ...
In China, how does FoundationONE NGS sequencing compare to common “hotspot panels” with respect to detecting clinically actionable alterations? How does FoundationONE technology differ from “hotspot” panels?
Exactly what does it mean that a tumor sample has a mutation or rearrangement? Exactly what is being measured? Is the presence of a mutation an “all-or–none” phenomenon or are there additional quantitative levels of characterization available ...
Does hybrid capture-based next-generation sequencing (NGS) have special application for detecting actionable genomic alterations in lung adenocarcinoma?
For what specific solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying mutations that can reliably guide the use of molecularly targeted therapy?
In what important ways does NGS address the fundamental changes that systemic cancer treatment is undergoing, i.e., toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types?
At what stage in the presentation of NSCLC should one consider doing comprehensive NGS with hybrid capture?
What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase (ROS1) as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected? What is the role of crizotinib in these patients?
If MET amplification is documented in NSCLC, why is crizotinib considered by the NCCN to have “targeted activity” against this tumor profile? What clinical study-based support—improvements in PFS and/or OS—suggests high activity of this ...
How, in the setting of lung cancer, specifically should oncologists optimally deploy specific NGS technologies, especially those that use hybrid capture to identify molecular drivers of NSCLC in the clinic?